Literature DB >> 17205324

[Clinical pharmacology of analgesics].

E Haen1.   

Abstract

The orthopedist can choose from three classes of drugs to relieve pain. Nonsteroidal anti-inflammatory drugs (NSAID) possess sufficient analgetic efficacy, but they are hampered by often causing gastrointestinal pain and bleeding. Opioids are strong analgetics that can be successfully used against strong pain. Their use is limited by spasms in both the gastrointestinal and the urinary tract causing constipation and retention of urine, respectively. A particular problem is respiratory depression that may be the ultimate cause of death in severely ill patients.Among nonacidic analgetics derivatives of pyrazole (e.g. dipyrone = metamizole) may also be used in situations associated with strong pain. Because of the risk of damage to white blood cells leading to agranulocytosis with foudroyant infections their use should be strictly limited to conditions that justify such a risk like tumor or colic pain. The aniline derivative acetaminophen (= paracetamol) is well tolerated and is the drug of choice in usual common pain. Large doses are to be avoided because of liver damage, especially in children.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17205324     DOI: 10.1007/s00132-006-1023-x

Source DB:  PubMed          Journal:  Orthopade        ISSN: 0085-4530            Impact factor:   1.087


  10 in total

Review 1.  Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.

Authors:  M M Wolfe; D R Lichtenstein; G Singh
Journal:  N Engl J Med       Date:  1999-06-17       Impact factor: 91.245

2.  Dipyrone and agranulocytosis: what is the risk?

Authors:  Jayne E Edwards; Henry J McQuay
Journal:  Lancet       Date:  2002-11-09       Impact factor: 79.321

Review 3.  THE CLINICAL EVALUATION OF MORPHINE AND ITS SUBSTITUTES AS ANALGESICS.

Authors:  L LASAGNA
Journal:  Pharmacol Rev       Date:  1964-03       Impact factor: 25.468

4.  Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs.

Authors:  L A García Rodríguez; H Jick
Journal:  Lancet       Date:  1994-03-26       Impact factor: 79.321

5.  Population-based drug-induced agranulocytosis.

Authors:  Luisa Ibáñez; Xavier Vidal; Elena Ballarín; Joan-Ramon Laporte
Journal:  Arch Intern Med       Date:  2005-04-25

6.  Agranulocytosis and other blood dyscrasias associated with dipyrone (metamizole).

Authors:  Karin Hedenmalm; Olav Spigset
Journal:  Eur J Clin Pharmacol       Date:  2002-06-06       Impact factor: 2.953

Review 7.  Life-threatening idiosyncratic drug-induced agranulocytosis in elderly patients.

Authors:  Emmanuel Andrès; Esther Noel; Jean-Emmanuel Kurtz; Nourredine Henoun Loukili; Georges Kaltenbach; Frédéric Maloisel
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

8.  Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study.

Authors:  Detlev F J Zech; Stefan Grond; John Lynch; Dagmar Hertel; Klaus A Lehmann
Journal:  Pain       Date:  1995-10       Impact factor: 6.961

9.  Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs.

Authors:  M J Langman; J Weil; P Wainwright; D H Lawson; M D Rawlins; R F Logan; M Murphy; M P Vessey; D G Colin-Jones
Journal:  Lancet       Date:  1994-04-30       Impact factor: 79.321

10.  Morphine and alternative opioids in cancer pain: the EAPC recommendations.

Authors:  G W Hanks; F Conno; N Cherny; M Hanna; E Kalso; H J McQuay; S Mercadante; J Meynadier; P Poulain; C Ripamonti; L Radbruch; J R Casas; J Sawe; R G Twycross; V Ventafridda
Journal:  Br J Cancer       Date:  2001-03-02       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.